Literature DB >> 14714745

Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole.

Fereidoun Azizi1, Majid Bahrainian, Mohammad E Khamseh, Mohsen Khoshniat.   

Abstract

OBJECTIVE: Recent studies have shown normal thyroid function in infants whose mothers receive methimazole (MMI) during breast-feeding. This study evaluates the long-term effect of MMI on thyroid function and intellectual development of such children. DESIGN AND METHODS: Eighty-two children aged between 48 and 86 months were studied. Forty-two children had been breast-fed while their thyrotoxic lactating mothers received daily doses of MMI 20-30 mg in the first, 10 mg in the second and 5-10 mg for additional 10 months of therapy. Thyroid function of infants remained normal during the one year of MMI therapy of their mothers. Forty other infants served as controls. Serum T4, T3, and TSH concentrations, urinary iodine, thyroid antibodies, intelligence quotient (IQ), verbal and functional (performance) components (Wechsler and Goodenough tests) were measured in all children of the two groups.
RESULTS: Height, weight, serum T4, T3, TSH and antithyroid antibody titers were not different between children in the two groups. The mean IQ was 107 +/- 17 vs 106 +/- 16 (Goodenough test) and 103 +/- 10 vs 103 +/- 16 (Wechsler test) for children of thyrotoxic mothers and control children, respectively. There was no difference in verbal and functional IQ and their components between children of thyrotoxic MMI treated mothers and control children.
CONCLUSION: Thyroid function and physical and intellectual development of breast-fed infants whose thyrotoxic lactating mothers were treated with 20-30 mg doses of MMI daily are normal at age 48 to 86 months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714745     DOI: 10.1515/jpem.2003.16.9.1239

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  7 in total

1.  Treatment of post-partum thyrotoxicosis.

Authors:  F Azizi
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum.

Authors:  Alex Stagnaro-Green; Marcos Abalovich; Erik Alexander; Fereidoun Azizi; Jorge Mestman; Roberto Negro; Angelita Nixon; Elizabeth N Pearce; Offie P Soldin; Scott Sullivan; Wilmar Wiersinga
Journal:  Thyroid       Date:  2011-07-25       Impact factor: 6.568

3.  Management of Hyperthyroidism in Pregnancy: Results of a Survey among Members of the European Thyroid Association.

Authors:  Kris Poppe; Alicja Hubalewska-Dydejczyk; Peter Laurberg; Roberto Negro; Francesco Vermiglio; Bijay Vaidya
Journal:  Eur Thyroid J       Date:  2012-02-29

4.  Pharmacologic treatment of hyperthyroidism during lactation.

Authors:  Miguel Marcelo Glatstein; Facundo Garcia-Bournissen; Norberto Giglio; Yaron Finkelstein; Gideon Koren
Journal:  Can Fam Physician       Date:  2009-08       Impact factor: 3.275

5.  Gestational and early postnatal hypothyroidism alters VGluT1 and VGAT bouton distribution in the neocortex and hippocampus, and behavior in rats.

Authors:  Daniela Navarro; Mayvi Alvarado; Francisco Navarrete; Manuel Giner; Maria Jesus Obregon; Jorge Manzanares; Pere Berbel
Journal:  Front Neuroanat       Date:  2015-02-17       Impact factor: 3.856

6.  Prevalent Practices of Thyroid Diseases During Pregnancy Among Endocrinologists, Internists and General Practitioners.

Authors:  Fereidoun Azizi; Ladan Mehran; Atieh Amouzegar; Shahram Alamdari; Imam Subetki; Navid Saadat; Siamak Moini; Farzaneh Sarvghadi
Journal:  Int J Endocrinol Metab       Date:  2015-11-07

7.  Management of hyperthyroidism in pregnancy: comparison of recommendations of american thyroid association and endocrine society.

Authors:  Shahram Alamdari; Fereidoun Azizi; Hossein Delshad; Farzaneh Sarvghadi; Atieh Amouzegar; Ladan Mehran
Journal:  J Thyroid Res       Date:  2013-05-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.